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Long-Term Reverse Remodeling
With Cardiac Resynchronization Therapy
Results of Extended Echocardiographic Follow-Up
David Verhaert, MD, Richard A. Grimm, DO, Chirapa Puntawangkoon, MD,
Kathy Wolski, MPH, Sabe De, MD, Bruce L. Wilkoff, MD, Randall C. Starling, MD, MPH,
W. H. Wilson Tang, MD, James D. Thomas, MD, Zoran B. Popovic´, MD, PHD
Cleveland, Ohio
Objectives The purpose of this study was to describe the long-term course of left ventricular remodeling induced by cardiac
resynchronization therapy (CRT), adjusting for the confounding effect of patient loss due to disease.
Background Reverse remodeling has been identified as the primary mechanism of improved symptoms and outcome in
heart failure patients.
Methods A total of 313 consecutive patients who underwent CRT with available baseline echocardiograms and subse-
quent clinical and echocardiographic follow-up were included in the analysis. Long-term follow-up included all-
cause mortality, heart transplantation, and implantation of a left ventricular assist device. Longitudinal data
analysis of left ventricular end-systolic volume index (LVESVi) was performed to adjust for the confounding effect
of patient loss during follow-up.
Results Patients with uneventful survival had a lower baseline LVESVi (  8.6 ml/m2, SE  4.6 ml/m2, p  0.0001)
and a decreased LVESVi by 0.11 ml/m2/day during first 6 months, whereas the LVESVi remained unchanged
in patients with adverse events (p  0.0001). Beyond 6 months, the LVESVi remained unchanged in patients
with uneventful survival, whereas the LVESVi continued to increase in those with adverse events at a rate of
0.01 ml/m2/day (p  0.0001). Predictors of reverse remodeling were nonischemic etiology, female sex, and a
wider QRS duration (p  0.0001, p  0.014, and p  0.001, respectively). In the majority of patients, 6 months
indicates a break point after which reverse remodeling becomes significantly less pronounced.
Conclusions CRT patients with uneventful survival show a significant decrease in the LVSVi at 6 months and generally main-
tain this response in the long term. Those with adverse outcomes are characterized by left ventricular dilation
despite CRT. (J Am Coll Cardiol 2010;55:1788–95) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.022a
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dhe beneficial effect of cardiac resynchronization therapy
CRT) for symptomatic patients with systolic heart failure
nd wide QRS complex has been shown in several clinical
rials (1–6). Evidence suggests that the improved outcomes
bserved with CRT are associated with reverse remodeling,
process characterized by a reduction in left ventricular
LV) volumes leading to improved systolic and diastolic
unction (7). The structural and functional changes associ-
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ccepted January 5, 2010.ted with this process occur as early as 3 months and are
ven more pronounced by 6 months, a time interval by
hich the magnitude of reverse remodeling has been shown
o predict the long-term prognosis in these patients (8–11).
lthough the MIRACLE (Multicenter InSync Random-
sed Clinical Evaluation) study showed that these beneficial
hanges are generally sustained at 12 months, this study also
emonstrated that LV volumes may increase at 1-year
ollow-up, particularly in the ischemic population (9). To
ur knowledge, no other studies have evaluated the tempo-
al course of LV reverse remodeling at a more extended
ollow-up. One of the problems arising with this type of
nalysis is that the evaluation of long-term response to CRT
s inherently confounded by the loss of patients during the
ollow-up period, most likely attributable to those with the
evelopment of minimal or no reverse remodeling.
The main purpose of the present study was to overcomehis limitation and investigate serial changes in LV size and
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April 27, 2010:1788–95 Reverse Remodeling in CRTunction by using longitudinal data analysis in a consecutive
ohort of patients with long-term follow-up. We also
ought to identify the clinical determinants of these time-
ependent changes, including potential modifiers of LV
emodeling after the first 6 months of CRT. Our final
bjective was to relate the course of LV remodeling with
ong-term outcome in CRT patients.
ethods
tudy population and study design. The records of all
eart failure patients who underwent CRT device implan-
ation at the Cleveland Clinic between January 2003 and
une 2006 were reviewed for this study. The criteria applied
or CRT in our institution include recent New York Heart
ssociation (NYHA) functional class III/IV symptoms
espite optimal medical therapy, QRS width 120 ms, and
V ejection fraction 35%. From this population, we
ncluded patients who had longitudinal follow-up at our
nstitution. Patients were excluded if no baseline transtho-
acic echocardiographic study was performed at the Cleve-
and Clinic before implantation. The minimal echocardio-
raphic follow-up required for inclusion was set at 90 days
fter the procedure; patients with a major event during these
rst 3 months (early death or urgent transplantation) were
xcluded. Patients with a device implanted before 2003
ndergoing exchange of their battery during the specified
eriod for any reason (end of life or previous removal of a
evice due to endocarditis) were also excluded.
The etiology of heart failure was considered ischemic on
he basis of a clinical history of myocardial infarction (with
lectrocardiographic evidence of infarct location) or a his-
ory of revascularization. In a subset of patients with
schemic cardiomyopathy who underwent myocardial via-
ility testing by single-photon emission computed tomog-
aphy or positron emission tomography with fluorodeoxy-
lucose before CRT, scar burden was quantified as a
ercentage of the total myocardium using the 17-segment
olar map (12). LV lead position was assessed by reviewing
ateral chest radiographs obtained after implantation, cate-
orizing the LV lead position as anterior, lateral, or poste-
ior (13).
The primary end point was a composite of death from any
ause (determined with the Social Security Death Index),
eed of heart transplantation, and support with a left
entricular assist device (LVAD). The study protocol was
pproved by the Cleveland Clinic Institutional Review
oard.
evice implantation and programming. Patients consid-
red at risk of sudden cardiac death received CRT including
n implantable cardioverter-defibrillator. Transvenous lead
ositioning was guided by venography with a preference for
lateral or posterolateral vein as an implantation site. In
ase of failure of or technical difficulties with the trans-
enous approach, an epicardial steroid-eluting passive lead
as implanted through a limited thoracotomy. The atrioven- sricular delay was routinely opti-
ized before discharge with the
ssistance of a device programmer
nd a cardiac sonographer, target-
ng stage I diastolic filling by
oppler mitral inflow (14).
chocardiographic analysis.
aseline and every subsequent
chocardiogram obtained at our
nstitution during the follow-up
f the patient after initiation CRT
ere systematically reviewed and
easured by 2 experienced read-
rs. The 2- and 4-chamber images were used to calculate left
entricular end-diastolic volume, left ventricular end-
ystolic volume, and left ventricular ejection fraction using
impson’s biplane method (15). Volumes were indexed
ccording to body surface area. The interobserver variability
nd intraobserver variability for volume analysis were deter-
ined from 49 random studies.
The severity of mitral regurgitation was measured from
he apical 4-chamber view. The left atrial and mitral
egurgitant jet areas were measured by planimetry, allowing
alculation of the ratio of jet/left atrial area (16). Mitral
egurgitation severity was graded as 0 (none), 1 (jet/left
trial area 10%), 2 (jet/left atrial area 10% to 20%), 3
jet/left atrial area 20% to 45%), and 4 (jet/left atrial area
45%). LV mechanical dyssynchrony was not consistently
ssessed in all patients before CRT.
tatistical methods. Detailed statistical methods are avail-
ble (Online Appendix). Briefly, to assess the evolution of
eft ventricular end-systolic volume index (LVESVi) during
RT, we applied a linear mixed effects model with unstruc-
ured covariance for random effects (SPSS Inc., Chicago,
llinois) (17). In a first step, we assessed the impact of CRT
n LVESVi. On the basis of the MIRACLE data (9), the
stimated LVESVi curve with CRT was assumed to flatten
ut after showing an initial decrease. Piecewise linear
egression was used to model the effect of time for both
xed and random effects, with potential break points of 90,
80, 360, and 720 days being tested. Minimal likelihood
atio was used to select optimal break point. In a second
tep, we assessed whether the group of patients with an
dverse event (death, heart transplantation, or LVAD im-
lantation) had a different LVESVi evolution after CRT. In
third step, we tested the impact of potential prognostic
ariables selected by survival analysis.
To assess prognostic variables, we performed a stepwise
ox proportional hazards regression with the combined end
oint of death, heart transplantation, and LVAD implan-
ation. Variables assessed as potential predictors included
ge, sex, NYHA functional class, QRS duration, heart
ailure etiology, and baseline LVESVi.
To assess determinants of late (180 days) changes in
VESVi, in a total of 197 patients with at least 2 additional
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
LV  left ventricular
LVAD  left ventricular
assist device
LVESVi  left ventricular
end-systolic volume index
NYHA  New York Heart
Associationtudies obtained 180 days after the start of CRT, we
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Reverse Remodeling in CRT April 27, 2010:1788–95alculated the slopes of the individual LVESVi/time rela-
ionships, with only the data obtained after 180 days for this
nalysis. We subsequently used forward stepwise multiple
inear regression to assess possible predictors (i.e., age, sex,
RS duration, initial LVESVi, heart failure etiology) of the
lopes of the individual LVESVi/time relationships.
The interobserver variability and intraobserver variability
ere expressed as the SD of the difference between 2 paired
easurements and as a percentage of variability (SD divided
y the average value).
Standard variables in the text are reported as mean SD,
nless otherwise specified, and as 95% confidence intervals
n the figures. The slopes of regression lines obtained by
ongitudinal data analysis are presented along with the
orresponding SE of the estimate. A p value of 0.05 was
aken to represent significance, except for third-order inter-
ctions, where p value of 0.2 was taken to represent
ignificance.
esults
atients. Of the 1,067 consecutive patients undergoing
RT device implantation between January 2003 and June
006 at the Cleveland Clinic, 337 (31.5%) met the pre-
pecified inclusion criteria. An additional 24 patients were
xcluded due to poor image quality, resulting in a cohort of
13 patients. The baseline characteristics of our study
atients and of the excluded population are described in
able 1. Although a major event within the first 90 days
fter implantation was one of the exclusion criteria, survival
t 1-, 2-, and 3-year follow-up was eventually fairly similar
or study patients compared with excluded patients (94%,
3%, and 72% vs. 86%, 78%, and 73%, respectively; p 
.46 by log-rank statistics).
During a follow-up of 1,301  573 days (range 111 to
,192 days), 118 (37.6%) study patients reached the end
oint (n  102, n  12, and n  4 for death, heart
ransplantation, and LVAD implantation, respectively).
Twenty-nine study patients received CRT despite being
n NYHA functional class II just before pacemaker implan-
ation, according to the clinicians’ discretion. Also, in 12
atients, CRT was started, although the electrocardiogram
mmediately before implantation showed a QRS complex
uration of 120 ms because of either intermittent left
undle branch block (n  3), requirement of pacemaker
mplantation while having heart failure and an ejection
raction 35%, or in 5 patients because of significant
ntraventricular dyssynchrony (assessed by echocardiography
t the specific request of the heart failure physician to
etermine whether they might benefit from CRT) (18,19).
stimated LVESVi curve for the whole study cohort.
igure 1 shows the observed values of the LVESVi during
RT superimposed with the fitted line obtained by piece-
ise regression. The optimal break point for the piecewise
egression was found to be at 180 days. Using this break
oint, both the initial slope of the change in the LVESVi snd the subsequent change in this initial slope after 6
onths were highly significant (p  0.0001 for all). In
ddition, the absolute values of the initial slope of the
VESVi changes and the subsequent change in the initial
lope over time were similar (0.063  0.008 ml/m2/day and
0.061  0.008 ml/m2/day, p  0.86 by the Wald test),
ndicating that piecewise linear regression with 2 indepen-
ent slopes could be substituted by piecewise linear regres-
ion with the second slope parallel to the x axis (see section
n statistical methods). In other words, after an initial
ecrease in the LVESVi, a break point is reached at 6
onths, after which the course of the LVESVi for the entire
tudy cohort remained unchanged. The mean decrease in
he LVESVi observed during the first 12 months after CRT
as 13.1  26%.
stimated LVESVi curves for patients with and without
dverse events. Next, we compared the changes in the
VESVi in patients with survival with patients who died or
nderwent heart transplantation or LVAD implantation.
atients who reached the combined end point had a
ignificantly larger initial LVESVi (by 18.6 ml/m2, SE 
.6 ml/m2, p  0.0001) (Fig. 2). Importantly, during the
nitial 6 months, patients with an uneventful survival dem-
nstrated a decrease in the LVESVi by 0.11 ml/m2/day,
hereas the LVESVi was slightly increased in patients with
dverse events (p  0.0001 for the difference in initial
aseline Characteristics of thetudy Cohort nd Excluded PatientsTable 1 B seline Charact r stics of theStudy Cohort and Excluded Patients
Study Cohort
(n  313)
Excluded Patients
(n  754)
Male sex (%) 69 73
Ischemic etiology (%) 52 60*
Age (yrs) 64.6 11.8 67.7 11.8†
NYHA functional class
II/III/IV (%)
8/83/9 10/72/8
LVEF (%) 26 10 24 10‡
LVESVi (ml/m2) 93 40 86 40‡
MR severity: 0/1/2/3/4 93/94/78/35/13 156/263/179/120/36
Previous mitral valve surgery
(repair/replacement)
18/5 78/12
Sinus rhythm (%) 81 78
QRS width (ms) 162 29 159 31
LBBB or continuous RV
pacing (%)
72 76
Scar burden (%)§ 34.4 19.5 33.3 17.0
ICD (%) 93 89
ACEI/ARB (%) 86 84
Beta-blockers (%) 85 83
Posterior/lateral/anterior
lead position (%)
67.0/28.6/4.4 59.0/36.1/4.9
ontinuous variables are given as mean SD and categorical variables as percentage. *p 0.05.
p  0.001. ‡p  0.01. §Based on positron emission tomography/single-photon emission
omputed tomography viability studies performed in a subgroup of 131 patients with ischemic
ardiomyopathy.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; ICD 
mplantable cardioverter-defibrillator; LBBB  left bundle branch block; LVEF  left ventricular
jection fraction; LVESVi  left ventricular end-systolic volume index at baseline; MR  mitral
egurgitation; NYHA  New York Heart Association; RV  right ventricle.lopes). Similarly, after 6 months, survivors showed stable
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April 27, 2010:1788–95 Reverse Remodeling in CRTolumes, whereas the LVESVi continued to increase in
onsurvivors at an average rate of 0.01 ml/m2/day (p 
.0001 for the difference in the late slopes).
urvival analysis. Because the final outcome cannot be
sed as a predictor of the change in the LVESVi, a Cox
odel was used to identify survival predictors and to
etermine whether these could serve as predictors of
VESVi changes after CRT. Table 2 shows 5 significant
ultivariable predictors of outcome. Baseline mitral regur-
itation severity did not predict an adverse outcome (p 
.13).
Although LV lead position was not included in the
nalysis because this information was available for only 255
82%) of our patients, a small impact of lead position on
utcome was observed in a univariable Cox model (p 0.04
or the difference between posterior, lateral, and anterior
ocations). Additionally, in 131 ischemic patients who had
n imaging evaluation of myocardial scarring, scar burden
lso was found to be a significant predictor of outcome (p
.003).
redictors of the course of LV remodeling. We then
ichotomized the continuous predictors of outcome as
escribed in the statistical methods section. Although
YHA class was the strongest predictor, it was not possible
o dichotomize this variable in an adequate manner because
ost of the patients were in NYHA functional class III
50
70
90
110
130
150
0 400 900 1400
Follow-up (Days)
LV
ES
Vi
(m
L/m
2 )
Follow-up (days): pre 1-30 120-249 250-499 500-999 >1000
All Patients (n) 313 190 130 182 237 189
Figure 1 Estimated Course of LVESVi
for the Entire Study Cohort (n  313)
Markers represent the average of the observed data obtained before implanta-
tion (time zero) over the intervals of 1 to 30 days, 120 to 249 days, 250 to
499 days, 500 to 999 days, and 1,000 days. Error bars represent 95% con-
fidence intervals. Piecewise regression line is obtained by mixed model
approach (see statistical methods for details). After a decrease during the
initial 6 months, the regression line becomes flat (p  0.1 for the slope of
regression line compared with 0°). LVESVi  left ventricular end-systolic
volume index.Table 2). Despite being a strong predictor of survival, theaseline LVESVi did not influence the change in the
VESVi during follow-up.
Figures 3A and 3B show the impact of heart failure
tiology and sex on LVESVi changes during follow-up.
ale patients and patients with ischemic etiology had a
ignificantly smaller decrease in the LVESVi during the
nitial 6 months (p  0.0001 and p  0.014 for the
ifference in initial slopes, respectively). Furthermore, dur-
ng the initial 6 months, female nonischemic patients
xperienced a larger LVESVi decrease (i.e., more reverse
emodeling) than other groups of patients (p  0.06 for
nteraction in the difference in initial slopes).
Figure 4 shows the impact of QRS duration on LVESVi
hanges during follow-up. Patients with a QRS duration
140 ms had significantly less LVESVi decrease during the
rst 6 months (p 0.001 for the difference in initial slopes).
o interaction was detected between QRS duration and
ither sex or heart failure etiology. Furthermore, ischemic
atients with scarring involving 32.5% of the total myo-
ardium also had a significantly smaller decrease in the
VESVi during the first 6 months after CRT (p  0.005
or the difference in initial slopes).
ate changes in LVESVi. We assessed determinants of
V remodeling after the initial 6 months of follow-up in
97 patients with data available to calculate late changes in
he LVESVi. The slope of the average change in the
VESVi after 6 months was 0.0078  0.054 ml/m2/day
p  NS vs. 0), indicating that, on average, the LVESVi
Follow-up (Days)
50
70
90
110
130
150
0 400 900 1400
Event-free (n = 195)
With Event (n = 118)
p < 0.0001
Follow-up (days): pre 1-30 120-249 250-499 500-999 >1000
With Event (n) 118 67 56 61 69 31
Event Free (n) 195 123 74 121 168 158 
Figure 2
Estimated Course of LVESVi for Patients With an Event-
Free Survival Versus Patients With Adverse Events
(Death, Heart Transplantation, or the Need for an LVAD)
Graph is drawn as in Figure 1. Patients with event-free survival show a large
initial LVESVi decrease, with the regression line becoming flat afterward. In
contrast, patients with adverse events show a small LVESVi increase during
the first 6 months, continuing approximately at the same rate throughout the
rest of follow-up (p  0.0001 for the difference in the course of the LVESVi
during both the initial 6 months and during late follow-up). LVAD  left ventric-
ular assist device; LVESVi  left ventricular end-systolic volume index.
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Reverse Remodeling in CRT April 27, 2010:1788–95emained stable after 180 days. In a univariable analysis,
nly the initial LVESVi (r 0.15, p 0.04) showed a weak
ositive correlation with a late increase in the LVESVi,
uggesting that late recurrent dilation tended to develop in
atients with a larger initial LVESVi, whereas the opposite
as true for patients with a smaller initial LVESVi (Fig. 5).
nterobserver and intraobserver variability. For LV end-
ystolic volume, the intraobserver variability and interob-
erver variability were 8  8 ml (5  5%) and 16  12 ml
10  8%), respectively.
iscussion
he main findings of our study, which focused on the
ong-term course of LV remodeling after CRT, are as
Nonischemic Patients
30
50
70
90
110
130
0 400 900 1400
Follow-up (Days)
LV
ES
Vi
(m
L/m
2 )
Women (n=69)
Men (n=79)
A
Follow-up (d): pre 1-30 120-249 250-499 500-999 >1000
Men                 79 56 34 50 60 52
Women 69 38       32 47              65 49 
Figure 3 Estimated Course of LVESVi for Patients With and Wi
Estimated course of left ventricular end-systolic volume index (LVESVi) for patients
Patients are stratified according to sex. Graphs are drawn as in Figure 1. Female s
first 6 months (p  0.0001 and p  0.014, respectively, for the difference in initi
ischemic patients (p  0.06 for interaction in initial slopes of LVESVi change; for
emic versus ischemic; p  0.06 for gender  etiology interaction.
ultivariable Cox Proportional Regression Analysishowing Significant Predictors of Outcome (Death,eart T ansplant, or Left Ventricular A sist Devicemplantation) i Ca diac R syn hronization Th rapyatie s
Table 2
Multivariable Cox Proportional Regression Analysis
Showing Significant Predictors of Outcome (Death,
Heart Transplant, or Left Ventricular Assist Device
Implantation) in Cardiac Resynchronization Therapy
Patients
Beta SE Wald p Value
NYHA functional class III 0.873 0.258 11.44651 0.0007
LVESVi (ml/m2) 0.007 0.002 10.59364 0.0011
Ischemic etiology 0.656 0.208 9.912443 0.0016
Male sex 0.714 0.268 7.097843 0.0077
QRS duration (ms) 0.009 0.003 6.937096 0.0084
ariables are presented in order of strength of relationship. The presence of higher functional class,
arger end-systolic volume, ischemic etiology, male sex, and shorter QRS duration predicted worse
utcome of patients undergoing resynchronization therapy.
Abbreviations as in Table 1.ollows. At 6 months, a break point was observed after
hich additional changes in the LVESVi became much less
ronounced. Female sex and a nonischemic etiology of heart
ailure were associated with a much greater initial response
Ischemic Patients
30
50
70
90
110
130
0 400 900 1400
Follow-up (Days)
LV
ES
Vi
(m
L/m
2 )
Women (n=28)
Men (n=137)
B 
ollow-up (d): pre 1-30 120-249 250-499 500-999 >1000
en            137 84     55 71 88 63
omen 28 12 9 14 24 25 
Ischemic Heart Disease as the Cause of Heart Failure
A) and without (B) ischemic heart disease as the cause of heart failure.
d nonischemic etiology were associated with a larger LVESVi decrease during the
es of LVESVi change). This decrease was even more prominent in female non-
, see statistical methods). p  0.0001 women versus men; p  0.014 nonisch-
Figure 4 Estimated Course of LVESVi for
Patients Stratified According to QRS Duration
Graph is drawn as in Figure 1. A significant difference in the initial left ventricu-
lar end-systolic volume index (LVESVi) decrease was observed with a cutoff
value of 140 ms (p  0.001 for the difference in initial slopes of LVESVi
change).F
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April 27, 2010:1788–95 Reverse Remodeling in CRTo CRT. Equally, patients with a baseline QRS duration
140 ms or ischemic patients with a smaller scar burden
xperienced a greater initial decrease in the LVESVi.
lthough, on average, the LVESVi seemed to be constant
t late follow-up, a weak trend for the development of late
ecurrent dilation was seen in patients with initially large
entricles and vice versa.
RT and long-term remodeling. Despite the survival
enefit of CRT for patients with advanced heart failure, the
umulative mortality is still high in this group of patients,
anging from 15% to 18% at 1 to 2 years in randomized,
ontrolled trials to 34% or higher at 5-year follow-up, as
ound by some observational studies (3,5,20). The substan-
ial loss of patients creates a challenge when presenting
ong-term follow-up data on LV remodeling because the
xtent of reverse remodeling has been shown to be corre-
ated with long-term prognosis in CRT patients (10,11).
aradoxically, this may lead to the false conclusion that LV
olumes continue to decrease with CRT even after more
han 2 years, whereas, in fact, only patients with a better
esponse are represented in these data.
Another problem with observational studies is that the
iming interval between (clinically indicated) studies is often
ariable, which complicates comparison of serial LV volume
hanges between patients during long-term follow-up. In
he present study, we addressed these methodological diffi-
ulties by applying a linear mixed effects model that allowed
s to analyze long-term changes in cardiac structure and
unction with CRT in a truly longitudinal fashion, leading
o results that are still robust in the setting of sampling
ariability and inherent patient dropout due to disease. This
-0.06
-0.04
-0.02
0
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0.04
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r= 0.15
n = 197
p = 0.04
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Figure 5
Correlation Between Late Changes in
the LVESVi (Changes Occurring After the
Initial 180 Days After CRT) and Baseline LVESVi
Correlation between late changes in the left ventricular end-systolic volume
index (LVESVi) (changes occurring after the initial 180 days after cardiac resyn-
chronization therapy [CRT]) and baseline LVESVi.pproach further extends our knowledge of the course of LV uemodeling, which until now was mostly limited to 12 to 18
onths of follow-up (9,21).
The first important finding in our analysis is that the
VESVi curve for the whole study population shows an
brupt decrease immediately after initiation of CRT and
hat this decrease continues until 6 months after implanta-
ion. At 6 months, a clear break point was observed, with
he LVESVi remaining relatively unchanged throughout
he rest of follow-up. Patients with an uneventful survival
howed a similar pattern of response with a more pro-
ounced decrease in the LVESVi during the first 6 months.
n contrast, patients with adverse events demonstrated a
arkedly different course of LV remodeling with the
VESVi remaining initially unchanged at best and subse-
uently showing a steady increase despite CRT. These
ndings add evidence to the concept that the process of
everse remodeling itself is directly associated with progno-
is of CRT, even in mildly symptomatic patients (22). The
linical implication of our results is that they provide a clear
ationale for performing echocardiography at 6 months of
RT as means of risk stratification and as a method to
redict the future course of LV remodeling. Based on these
esults, patients who do not show a decrease in the LVESVi
t 6 months are unlikely to do so thereafter, a finding that
as a significant impact on subsequent management of these
atients. We have shown that the rate of adverse events in
his population may be lowered by referring these patients to
multidisciplinary CRT optimization clinic to uncover
eversible causes of a suboptimal response to CRT (e.g.,
hythm abnormalities, suboptimal lead positioning, device
rogramming, suboptimal indications for CRT) (23). Our
esults indicate that the 6-month time point may be the
ptimal time to refer selected patients for an evaluation of
onresponse as a step in their further clinical management.
eterminants of CRT-induced remodeling. Another
mportant goal of this study was to identify clinical deter-
inants of these time-dependent changes in LV size and
unction secondary to CRT. Because outcome was signifi-
antly associated with a change in the LVESVi after CRT,
any variables associated with long-term outcome in our
opulation were also found to have a direct effect on the
ime course of LV remodeling.
Similar to previous findings, patients with ischemic heart
isease demonstrated less improvement in LV function
uring the first 6 months (8,9). However, whereas the
IRACLE study found that the beneficial decrease in LV
olumes seen at 6 months had partially regressed by 12
onths in the ischemic population, our longer term
ollow-up indicates that there is no precise point in time
here the initial benefit of CRT is eventually offset by
ecurrent late LV dilation, which could have reflected the
atural history of ischemic cardiomyopathy. Our findings
lso help to explain why the beneficial effects of CRT on
ymptoms, quality of life, morbidity, and mortality are still
reserved in the ischemic population at long-term follow-
p, as shown previously (5,21).
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Reverse Remodeling in CRT April 27, 2010:1788–95Furthermore, although heart failure patients should not
e denied CRT on the basis of an ischemic etiology alone,
ur data also suggest that it may be wise to consider scar
urden before offering CRT in this subgroup of patients. In
hose patients who underwent viability testing by positron
mission tomography with fluorodeoxyglucose or single-
hoton emission computed tomography before device im-
lantation, more extensive LV scarring was clearly associ-
ted with less favorable late remodeling and a worse
utcome. Large prospective studies are certainly needed to
etter define the optimal threshold of scar burden above
hich CRT is unlikely to result in significant reverse
emodeling.
Female sex was a strong and independent predictor of
utcome in the total population and of the extent of reverse
emodeling in the subgroup of patients with nonischemic
ardiomyopathy. Epidemiological (24) and placebo-
ontrolled clinical (25–27) trials have demonstrated that
omen with heart failure generally have a better survival
han men, irrespective of the underlying etiology. However,
o our knowledge, only 1 other observational registry has
eported on sex-related differences in LV reverse remodeling
fter CRT (28). The exact mechanism by which female
atients with nonischemic cardiomyopathy experience a
etter response is yet unclear and deserves further investigation.
Finally, in patients with QRS duration 140 ms before
RT not only did less reverse remodeling develop, but they
lso experienced a worsened outcome. Although several
eports emphasized the limitations of QRS duration alone
s a surrogate for electromechanical dyssynchrony and
redictor of CRT response, some studies suggest that QRS
idth is a more robust predictor with increasing QRS
uration (5,8).
Our data as well as data from the RethinQ trial, which
ailed to demonstrate improved response rates to CRT
hen adding echocardiographic measures of dyssynchrony
19,29) to a QRS duration 120 ms, suggest that QRS
uration remains important and should not be marginalized
s a implantation criterion.
Interestingly, although patients with a higher baseline
VESVi had a worse outcome, the baseline LVESVi itself
as not an independent predictor of the overall course of
V remodeling. When we looked at late changes in the
VESVi (late is defined as 180 days) alone, we found a
eak but significant trend in patients with a higher baseline
VESVi toward the development of late recurrent LV
ilation. Other clinical variables, however, were not clearly
ssociated with the course of remodeling 180 days after
mplantation. This again suggests that the early effect of
RT is important for the long-term outcome in CRT
atients. After the first 6 months, changes become much
ess pronounced and do not seem to be strongly influenced
y a pre-procedure variable.
tudy limitations. A substantial proportion of patients
ho underwent CRT implantation at the Cleveland Clinic
ere not included in the analysis. The most common reasonor exclusion was the lack of follow-up, which reflects the
ature of the institution as a tertiary referral center. Al-
hough baseline characteristics and survival were fairly
imilar between the study population and the excluded
atients, a selection bias cannot be excluded.
Although reverse remodeling with a nonischemic heart
ailure etiology was more pronounced in women, it was very
imilar in men and women with an ischemic etiology.
owever, the number of women with an ischemic etiology
as small, and further studies are needed to clarify this issue.
The optimal break point was selected from among 4
lternatives using the optimal minimal likelihood ratio,
lthough this selection method does not ensure that the
elected point was significantly different from other possible
reak points.
Finally, this was a retrospective observational study,
mplying that treatment changes during follow-up may have
nfluenced outcomes. However, to include these effects in
he statistical model would have made the analysis even
ore complicated. In addition, we believe that the obser-
ational nature of the study makes the results more repre-
entative of real-world clinical practice.
onclusions
ollow-up and monitoring of LV volume changes in pa-
ients undergoing CRT provides incremental evidence of an
nfavorable course of LV remodeling in patients destined
or potentially adverse outcomes. Factors associated with
ess reverse remodeling include ischemic etiology, male sex,
nd QRS duration 140 ms before implantation. In the
ajority of patients, a break point is observed at 6 months
f CRT, after which favorable remodeling becomes much
ess pronounced.
eprint requests and correspondence: Dr. Zoran B. Popovic´,
epartment of Cardiovascular Medicine, Section of Cardiac Im-
ging, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio
4195. E-mail: popoviz@ccf.org.
EFERENCES
1. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchroniza-
tion in chronic heart failure. N Engl J Med 2002;346:1845–53.
2. Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of
hemodynamically optimized cardiac resynchronization therapy in pa-
tients with heart failure and ventricular conduction delay. J Am Coll
Cardiol 2002;39:2026–33.
3. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization
therapy with or without an implantable defibrillator in advanced
chronic heart failure. N Engl J Med 2004;350:2140–50.
4. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biven-
tricular pacing in patients with heart failure and intraventricular
conduction delay. N Engl J Med 2001;344:873–80.
5. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac
resynchronization on morbidity and mortality in heart failure. N Engl
J Med 2005;352:1539–49.
6. Young JB, Abraham WT, Smith AL, et al. Combined cardiac
resynchronization and implantable cardioversion defibrillation in ad-
vanced chronic heart failure: the MIRACLE ICD trial. JAMA
2003;289:2685–94.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
K
r
1795JACC Vol. 55, No. 17, 2010 Verhaert et al.
April 27, 2010:1788–95 Reverse Remodeling in CRT7. Sutton MS, Keane MG. Reverse remodelling in heart failure with
cardiac resynchronisation therapy. Heart 2007;93:167–71.
8. St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac
resynchronization therapy on left ventricular size and function in
chronic heart failure. Circulation 2003;107:1985–90.
9. Sutton MG, Plappert T, Hilpisch KE, Abraham WT, Hayes DL,
Chinchoy E. Sustained reverse left ventricular structural remodeling
with cardiac resynchronization at one year is a function of etiology:
quantitative Doppler echocardiographic evidence from the Multicenter
InSync Randomized Clinical Evaluation (MIRACLE). Circulation
2006;113:266–72.
0. Ypenburg C, van Bommel RJ, Borleffs CJ, et al. Long-term prognosis
after cardiac resynchronization therapy is related to the extent of left
ventricular reverse remodeling at midterm follow-up. J Am Coll
Cardiol 2009;53:483–90.
1. Yu CM, Bleeker GB, Fung JW, et al. Left ventricular reverse
remodeling but not clinical improvement predicts long-term survival
after cardiac resynchronization therapy. Circulation 2005;112:1580–6.
2. Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging
predicts echocardiographic response to cardiac resynchronization ther-
apy in ischemic cardiomyopathy. Am Heart J 2007;153:105–12.
3. Wilton SB, Shibata MA, Sondergaard R, Cowan K, Semeniuk L,
Exner DV. Relationship between left ventricular lead position using a
simple radiographic classification scheme and long-term outcome with
resynchronization therapy. J Interv Card Electrophysiol 2008;23:
219–27.
4. Kedia N, Ng K, Apperson-Hansen C, et al. Usefulness of atrioven-
tricular delay optimization using Doppler assessment of mitral inflow
in patients undergoing cardiac resynchronization therapy. Am J
Cardiol 2006;98:780–5.
5. Schiller NB, Shah PM, Crawford M, et al. Recommendations for
quantitation of the left ventricle by two-dimensional echocardiogra-
phy. American Society of Echocardiography Committee on Standards,
Subcommittee on Quantitation of Two-Dimensional Echocardio-
grams. J Am Soc Echocardiogr 1989;2:358–67.
6. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations
for evaluation of the severity of native valvular regurgitation with
two-dimensional and Doppler echocardiography. J Am Soc Echocar-
diogr 2003;16:777–802.
7. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal
Analysis. Hoboken, NJ: John Wiley & Sons, 2004.
8. Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony
predicts response and prognosis after cardiac resynchronization ther-
apy. J Am Coll Cardiol 2004;44:1834–40. F9. Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization
therapy in heart failure with narrow QRS complexes. N Engl J Med
2007;357:2461–71.
0. Auricchio A, Metra M, Gasparini M, et al. Long-term survival of
patients with heart failure and ventricular conduction delay treated
with cardiac resynchronization therapy. Am J Cardiol 2007;99:232–8.
1. Wikstrom G, Blomstrom-Lundqvist C, Andren B, et al. The effects of
aetiology on outcome in patients treated with cardiac resynchroniza-
tion therapy in the CARE-HF trial. Eur Heart J 2009;30:782–8.
2. Linde C, Gold M, Abraham WT, Daubert JC. Baseline characteristics
of patients randomized in The Resynchronization Reverses Remodel-
ing In Systolic Left Ventricular Dysfunction (REVERSE) study.
Congest Heart Fail 2008;14:66–74.
3. Mullens W, Grimm RA, Verga T, et al. Insights from a cardiac
resynchronization optimization clinic as part of a heart failure disease
management program. J Am Coll Cardiol 2009;53:765–73.
4. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart
failure: the Framingham Study. J Am Coll Cardiol 1993;22:6A–13A.
5. Adams KF Jr., Sueta CA, Gheorghiade M, et al. Gender differences in
survival in advanced heart failure. Insights from the FIRST study.
Circulation 1999;99:1816–21.
6. Ghali JK, Krause-Steinrauf HJ, Adams KF, et al. Gender differences
in advanced heart failure: insights from the BEST study. J Am Coll
Cardiol 2003;42:2128–34.
7. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differ-
ences in the prognosis of congestive heart failure: results from the
Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001;
103:375–80.
8. Lilli A, Ricciardi G, Porciani MC, et al. Cardiac resynchronization
therapy: gender related differences in left ventricular reverse remodel-
ing. Pacing Clin Electrophysiol 2007;30:1349–55.
9. Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of
Response to CRT (PROSPECT) trial. Circulation 2008;117:
2608 –16.
ey Words: cardiac resynchronization therapy y heart failure y
emodeling.
APPENDIXor statistical methods, please see the online version of this article.
